

Vol. 6, No. 6

March 2008

ISSN 1359-6349

EJC Supplements

VEGF inhibition: changing the face of breast cancer management

The opinions and views expressed in this educational supplement are those of the authors and do not necessarily reflect the opinions or recommendations of F. Hoffmann–La Roche Ltd. The articles in this supplement may discuss dosages or uses of bevacizumab or other pharmaceutical agents that are not approved by regulatory authorities in Europe and elsewhere. Please consult local prescribing information before using any product.

The authors would like to thank F. Hoffmann–La Roche Ltd. for providing funding for the preparation of this work and Gardiner–Caldwell Communications for providing editorial support.

